These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31389210)

  • 1. Efficacy of Topical Cyclosporine Nanoemulsion 0.05% Compared with Topical Cyclosporine Emulsion 0.05% and Diquafosol 3% in Dry Eye.
    Park CH; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Lee HK; Chung TY; Choi CY; Kim HS
    Korean J Ophthalmol; 2019 Aug; 33(4):343-352. PubMed ID: 31389210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 0.05% cyclosporine and 3% diquafosol solution for dry eye patients: a randomized, blinded, multicenter clinical trial.
    Park CH; Lee HK; Kim MK; Kim EC; Kim JY; Kim TI; Kim HK; Song JS; Yoon KC; Lee DH; Chung TY; Choi CY; Kim HS
    BMC Ophthalmol; 2019 Jun; 19(1):131. PubMed ID: 31208393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry eye.
    Tauber J; Davitt WF; Bokosky JE; Nichols KK; Yerxa BR; Schaberg AE; LaVange LM; Mills-Wilson MC; Kellerman DJ
    Cornea; 2004 Nov; 23(8):784-92. PubMed ID: 15502479
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Effects and Safety of 3% Diquafosol Ophthalmic Solution for Patients With Dry Eye After Cataract Surgery: A Randomized Controlled Trial.
    Park DH; Chung JK; Seo DR; Lee SJ
    Am J Ophthalmol; 2016 Mar; 163():122-131.e2. PubMed ID: 26685791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in Human Tear Proteome Following Topical Treatment of Dry Eye Disease: Cyclosporine A Versus Diquafosol Tetrasodium.
    Ji YW; Kim HM; Ryu SY; Oh JW; Yeo A; Choi CY; Kim MJ; Song JS; Kim HS; Seo KY; Kim KP; Lee HK
    Invest Ophthalmol Vis Sci; 2019 Dec; 60(15):5035-5044. PubMed ID: 31800960
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Effect of Topical Diquafosol Tetrasodium 3% on Dry Eye After Cataract Surgery.
    Baek J; Doh SH; Chung SK
    Curr Eye Res; 2016 Oct; 41(10):1281-1285. PubMed ID: 27049809
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of diquafosol ophthalmic solution in patients with dry eye syndrome: a Japanese phase 2 clinical trial.
    Matsumoto Y; Ohashi Y; Watanabe H; Tsubota K;
    Ophthalmology; 2012 Oct; 119(10):1954-60. PubMed ID: 22739038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diquafosol sodium ophthalmic solution for the treatment of dry eye: clinical evaluation and biochemical analysis of tear composition.
    Shigeyasu C; Yamada M; Akune Y; Tsubota K
    Jpn J Ophthalmol; 2015 Nov; 59(6):415-20. PubMed ID: 26310103
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic effects of 3% diquafosol ophthalmic solution in patients with short tear film break-up time-type dry eye disease.
    Mun Y; Kwon JW; Oh JY
    BMC Ophthalmol; 2018 Sep; 18(1):237. PubMed ID: 30185156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changes in Tear Volume after 3% Diquafosol Treatment in Patients with Dry Eye Syndrome: An Anterior Segment Spectral-domain Optical Coherence Tomography Study.
    Lee KB; Koh KM; Kwon YA; Song SW; Kim BY; Chung JL
    Korean J Ophthalmol; 2017 Aug; 31(4):306-312. PubMed ID: 28752695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
    Yang JM; Choi W; Kim N; Yoon KC
    Optom Vis Sci; 2015 Sep; 92(9):e296-302. PubMed ID: 26107023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Efficacy of Diquafosol Ophthalmic Solution in Non-Sjögren and Sjögren Syndrome Dry Eye Patients Unresponsive to Artificial Tear.
    Jeon HS; Hyon JY
    J Ocul Pharmacol Ther; 2016 Sep; 32(7):463-8. PubMed ID: 27294831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of topical diquafosol ophthalmic solution for treatment of dry eye: a systematic review of randomized clinical trials.
    Wu D; Chen WQ; Li R; Wang Y
    Cornea; 2015 Jun; 34(6):644-50. PubMed ID: 25909234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of decreasing the dosage of cyclosporine A 0.05% on dry eye disease after 1 year of twice-daily therapy.
    Su MY; Perry HD; Barsam A; Perry AR; Donnenfeld ED; Wittpenn JR; D'Aversa G
    Cornea; 2011 Oct; 30(10):1098-104. PubMed ID: 21407074
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trial.
    Chen M; Gong L; Sun X; Xie H; Zhang Y; Zou L; Qu J; Li Y; He J
    J Ocul Pharmacol Ther; 2010 Aug; 26(4):361-6. PubMed ID: 20698799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of 3% diquafosol sodium eye drop application on meibomian gland and ocular surface alterations in the Cu, Zn-superoxide dismutase-1 (Sod1) knockout mice.
    Ikeda K; Simsek C; Kojima T; Higa K; Kawashima M; Dogru M; Shimizu T; Tsubota K; Shimazaki J
    Graefes Arch Clin Exp Ophthalmol; 2018 Apr; 256(4):739-750. PubMed ID: 29484560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-Term Effects of Ground-Level Ozone in Patients With Dry Eye Disease: A Prospective Clinical Study.
    Kim Y; Paik HJ; Kim MK; Choi YH; Kim DH
    Cornea; 2019 Dec; 38(12):1483-1488. PubMed ID: 31299662
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of the effect of diquafosol ophthalmic solution in glaucoma patients with dry eye syndrome.
    Jin SW; Min JS
    Jpn J Ophthalmol; 2016 May; 60(3):150-5. PubMed ID: 26873225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the Efficacy and Safety of A Novel 0.05% Cyclosporin A Topical Nanoemulsion in Primary Sjögren's Syndrome Dry Eye.
    Kang MJ; Kim YH; Chou M; Hwang J; Cheon EJ; Lee HJ; Chung SH
    Ocul Immunol Inflamm; 2020 Apr; 28(3):370-378. PubMed ID: 30986119
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.